Linda D. Bosserman, MD, FACP, president, medical oncologist, Wilshire Oncology Medical Group, discusses how she determines if a patient is resistant to a taxane or anthracyclines.
Linda D. Bosserman, MD, FACP
Advertisement
Articles by Linda D. Bosserman, MD, FACP
Linda D. Bosserman, MD, FACP, president, medical oncologist, Wilshire Oncology Medical Group, discusses how she would treat a patient with HER2-negative metastatic breast cancer.
Advertisement
Latest Updated Articles
Treating a Patient With HER2-Negative Metastatic Breast CancerPublished: August 13th 2014 | Updated:
Determining Resistance to a Taxane or Anthracyclines in Breast CancerPublished: August 13th 2014 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
